Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Tracy T. Batchelor; Elizabeth R. Gerstner; Xiaobu Ye; Serena Desideri; Daniel G. Duda; David Peereboom; Glenn J. Lesser; Sajeel Chowdhary; Patrick Y. Wen; Stuart Grossman; Jeffrey G. Supko

doi:10.1093/NEUONC/NOW185

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Tracy T. Batchelor, Elizabeth R. Gerstner, Xiaobu Ye, Serena Desideri, Daniel G. Duda, David Peereboom, Glenn J. Lesser, Sajeel Chowdhary, Patrick Y. Wen, Stuart Grossman, Jeffrey G. Supko

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	19
DOIs	https://doi.org/10.1093/NEUONC/NOW185
State	Published - Sep 23 2016
Externally published	Yes

Disciplines

Pharmacology
Endocrinology
Medicine and Health Sciences
Internal Medicine

Access to Document

10.1093/NEUONC/NOW185License: Unspecified

Cite this

Batchelor, T. T., Gerstner, E. R., Ye, X., Desideri, S., Duda, D. G., Peereboom, D., Lesser, G. J., Chowdhary, S., Wen, P. Y., Grossman, S., & Supko, J. G. (2016). Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro-oncology, 19. https://doi.org/10.1093/NEUONC/NOW185

Batchelor, TT, Gerstner, ER, Ye, X, Desideri, S, Duda, DG, Peereboom, D, Lesser, GJ, Chowdhary, S, Wen, PY, Grossman, S & Supko, JG 2016, 'Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.', Neuro-oncology, vol. 19. https://doi.org/10.1093/NEUONC/NOW185

@article{cf466493153e4129ad022e64e73b2a10,

title = "Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.",

author = "Batchelor, \{Tracy T.\} and Gerstner, \{Elizabeth R.\} and Xiaobu Ye and Serena Desideri and Duda, \{Daniel G.\} and David Peereboom and Lesser, \{Glenn J.\} and Sajeel Chowdhary and Wen, \{Patrick Y.\} and Stuart Grossman and Supko, \{Jeffrey G.\}",

note = "Tracy T. Batchelor,*, 1 Elizabeth R. Gerstner, *, 1 Xiaobu Ye, 1 Serena Desideri, 1 Daniel G. Duda, 1 David Peereboom, 1 Glenn J. Lesser, 1 Sajeel Chowdhary, 1 Patrick Y. Wen, 1 Stuart Grossman, 1 and Jeffrey G.",

year = "2016",

month = sep,

day = "23",

doi = "10.1093/NEUONC/NOW185",

language = "American English",

volume = "19",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

AU - Batchelor, Tracy T.

AU - Gerstner, Elizabeth R.

AU - Ye, Xiaobu

AU - Desideri, Serena

AU - Duda, Daniel G.

AU - Peereboom, David

AU - Lesser, Glenn J.

AU - Chowdhary, Sajeel

AU - Wen, Patrick Y.

AU - Grossman, Stuart

AU - Supko, Jeffrey G.

N1 - Tracy T. Batchelor,*, 1 Elizabeth R. Gerstner, *, 1 Xiaobu Ye, 1 Serena Desideri, 1 Daniel G. Duda, 1 David Peereboom, 1 Glenn J. Lesser, 1 Sajeel Chowdhary, 1 Patrick Y. Wen, 1 Stuart Grossman, 1 and Jeffrey G.

PY - 2016/9/23

Y1 - 2016/9/23

UR - http://europepmc.org/articles/PMC5464374

U2 - 10.1093/NEUONC/NOW185

DO - 10.1093/NEUONC/NOW185

M3 - Article

VL - 19

JO - Neuro-oncology

JF - Neuro-oncology

ER -

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Disciplines

Access to Document

Other files and links

Cite this